Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | Q9HBH1 | 2/20 | 0.32 | |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5103035 | 0.76 | DPP4 (0.53) | DPP4ALDH1A1TSHRPDF | |
| SCHEMBL26665617 | 0.76 | ALDH1A1 (0.33) | ALDH1A1TSHR | |
| SCHEMBL4956827 | 0.76 | DPP4 (0.53) | DPP4ALDH1A1TSHRPDF | |
| SCHEMBL22743972 | 0.75 | DPP4 (0.40) | DPP4TSHR | |
| SCHEMBL21325199 | 0.74 | DPP4 (0.33) | DPP4ALDH1A1TSHRPDF | |
| Hydrochloric Acid SCHEMBL3207817 | 0.74 | DPP4 (0.52) | DPP4ALDH1A1PDF | |
| Hydrochloric Acid SCHEMBL3207807 | 0.74 | DPP4 (0.52) | DPP4ALDH1A1PDF | |
| SCHEMBL12867291 | 0.72 | ALDH1A1 (0.38) | DPP4ALDH1A1TSHRPDF | |
| SCHEMBL14108242 | 0.72 | ALDH1A1 (0.38) | DPP4ALDH1A1TSHRPDF | |
| SCHEMBL26378526 | 0.72 | TP53 (0.33) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827634-B2 | Small molecule inhibitors of NF-kB inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-28 | — | — | US | disclosed |
| US-7601850-B2 | less hypercalcemic than 1a,25 dihydroxy vitamin D3; bone disorders, psoriasis | ELI LILLY AND COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| US-6743794-B2 | MULTIDRUG RESISTANCE PROTEIN; CANCER; 3-(9-CHLORO-3-METHYL-4-OXO-5H-ISOXAZOLO(4,3-C)QUINOLIN-5-YL)) CYCLOHEXYL)-2-PIPERIDYLACETAMIDE | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827634-B2 | Small molecule inhibitors of NF-kB inducing kinase | NFKBIA, IKBKB, NFRKB | DPP4 995/4885ALDH1A1 4109/4885TSHR 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.